What the Study Found (In Plain English)
Published in Rheumatology (Oxford, England) (2022), this phase iii randomized trial evaluating 527 human participants investigated: Apremilast monotherapy was evaluated up to 5 years in PALACE 4 (fourth PsA Long-term Assessment of Clinical Efficacy study) DMARD-naïve patients with PsA. Key clinical takeaway: Apremilast led to sustained PsA efficacy up to 260 weeks and was well tolerated.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Rheumatology (Oxford, England), 2022-03-02; N = 527; Rigor 93/100): Apremilast led to sustained PsA efficacy up to 260 weeks and was well tolerated.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.